Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis
| Autor: | Jeffrey W. Taub, Batool Al‐Qanber, Süreyya Savaşan, Yaddanapudi Ravindranath, Steven Buck, Manisha Gadgeel |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Acute leukemia
Down syndrome medicine.medical_specialty Hematology Myeloid business.industry Myeloid leukemia General Medicine medicine.disease 03 medical and health sciences chemistry.chemical_compound Leukemia 0302 clinical medicine Immunophenotyping medicine.anatomical_structure RUNX1 chemistry hemic and lymphatic diseases 030220 oncology & carcinogenesis Internal medicine Cancer research medicine business 030215 immunology |
| Zdroj: | Annals of Hematology. 100:1695-1700 |
| ISSN: | 1432-0584 0939-5555 |
| DOI: | 10.1007/s00277-021-04531-x |
| Popis: | Children with Down syndrome (DS) are at an increased risk of developing transient abnormal myelopoiesis (TAM) and acute leukemia. Aberrant expression of CD56 has been observed on myeloid leukemic blasts in DS patients. In general, CD56 expression in acute myeloid leukemia (AML) is considered a promoter of leukemogenesis. We did a retrospective flow cytometric study to investigate mature myelomonocytic cell CD56 expression patterns in TAM, non-TAM, and leukemia cases with DS. Flow cytometric analysis showed that granulocyte and monocyte aberrant/dysplastic CD56 expression is an inherent characteristic of most DS patients irrespective of the presence of TAM or leukemia. Increased CD56 expression in monocyte and granulocyte populations in DS could be multifactorial; greater expression of RUNX1 secondary to the gene dose effect of trisomy 21 along with the maturational state of the cells are the potential contributors. Unlike AML seen in non-DS patients, CD56 overexpression in DS AML cases does not appear to play a role in leukemogenesis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink